Is CapsoVision, Inc. Common Stock (CV) overvalued? · rev $3.5M
CapsoVision, Inc. Common Stock (CV) is a medical devices company listed on US.
This page asks whether CapsoVision, Inc. Common Stock (CV) looks expensive on cached numbers — not a short thesis.
Latest reported CV revenue for 2025-09-30 was $3.5M. Net income was -$7.9M. Revenue was up 6.7% from 2025-06-30 to 2025-09-30. CV currently screens at market cap $359.2M.
CV currently screens at market cap $359.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CV 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CV stock page for the full model, not this heading.
Not investment advice.